Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic Hematopoietic Stem Cell Transplantation (M.D. Anderson Regimen)
- Development stage
- Unknown
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules, Antibody-Based Therapeutics
01
Overview
This therapeutic regimen involves allogeneic hematopoietic stem cell transplantation (HSCT) preceded by a multi-agent intensive conditioning protocol. Developed by the M.D. Anderson Cancer Center, it is specifically designed for pediatric and adolescent-young adult (AYA) patients with high-risk, recurrent, or refractory solid tumors, including Ewing sarcoma, neuroblastoma, and rhabdomyosarcoma. The conditioning phase utilizes chemotherapy agents such as fludarabine, thiotepa, etoposide, and melphalan to eradicate malignant cells and suppress the host immune system, alongside rabbit anti-thymocyte globulin (ATG) for T-cell depletion. Following the infusion of donor stem cells, immunosuppressants like tacrolimus, cyclosporine, and mycophenolate mofetil are employed to manage graft-versus-host disease (GVHD). The treatment aims to leverage the graft-versus-tumor effect to achieve long-term remission in aggressive solid malignancies.
- Other names
- Allogeneic HSCT for Pediatric and AYA High-Risk Solid Tumors
Beyond the preview
Go deeper on Allogeneic Hematopoietic Stem Cell Transplantation (M.D. Anderson Regimen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic Hematopoietic Stem Cell Transplantation (M.D. Anderson Regimen).